SS-31 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
SS-31 (Elamipretide (SS-31)) is a Mitochondrial-targeting tetrapeptide researched for improved muscle strength, enhanced cardiac function, increased ATP production, reduced oxidative stress, restored age-related mitochondrial dysfunction. For beginners, start at the lower end of the dosage range (4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV) and administer daily subcutaneous or weekly IV infusion via subcutaneous injection or intravenous infusion.
What Is SS-31?
SS-31 (Elamipretide (SS-31)) is a Mitochondrial-targeting tetrapeptide. Synthetic tetrapeptide co-discovered for mitochondrial dysfunction disorders; developed by Stealth BioTherapeutics.
It is researched for its potential effects on improved muscle strength, enhanced cardiac function, increased ATP production, reduced oxidative stress, restored age-related mitochondrial dysfunction. The first FDA-approved mitochondrial-targeted therapy — directly addressing the fundamental mitochondrial dysfunction underlying multiple age-related and genetic diseases by stabilizing the inner membrane structure itself.
For beginners: This guide assumes no prior peptide experience. We'll cover everything from what SS-31 is to how to reconstitute, inject, and structure your first cycle.
How Does SS-31 Work?
Selectively binds cardiolipin in the inner mitochondrial membrane, stabilizing cristae structure and enhancing electron transfer efficiency. Reduces cytochrome C peroxidase activity, decreases reactive oxygen species production, increases ATP generation, and prevents apoptosis through mitochondrial outer membrane stabilization.
Understanding the mechanism helps set realistic expectations about what SS-31 can and cannot do.
How Do You Get Started With SS-31?
Step 1 — Source: Purchase SS-31 from a vendor with third-party Certificate of Analysis (COA) testing. This confirms purity (aim for 98%+) and rules out contamination.
Step 2 — Supplies: You'll need bacteriostatic water, insulin syringes (1mL/100-unit), alcohol swabs, and a clean workspace.
Step 3 — Reconstitute: Add BAC water to the SS-31 vial — use our peptide calculator for exact amounts. Let the water run down the side of the vial; never spray directly on the powder. Swirl gently.
Step 4 — Dose: Draw 4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV using the calculator's syringe unit conversion.
Step 5 — Inject: Clean the injection site with alcohol. Pinch a fold of abdominal fat and insert the needle at 45° for subcutaneous injection. Push the plunger slowly and hold for 5 seconds.
Calculate Your SS-31 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for SS-31.
Open Calculator →What Should Your First SS-31 Cycle Look Like?
Dosage: Start at the lower end of 4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV. This lets you assess tolerance before committing to a full cycle.
Frequency: daily subcutaneous or weekly IV infusion via subcutaneous injection or intravenous infusion.
Duration: 12-48 weeks in clinical trials. Don't cut cycles short — many Mitochondrial-targeting tetrapeptide effects take weeks to fully manifest.
Off-cycle: Plan a 4-week break before starting another cycle.
What Side Effects Should Beginners Watch For?
Excellent safety profile. No adverse events reported in single-dose IV studies. Well-tolerated across wide dose ranges in long-term Phase 2 and 3 trials.
As a beginner, track everything — dose, time, injection site, and any effects (positive or negative). This data helps optimize future cycles.
What Are Common Beginner Mistakes?
Not using BAC water: Sterile water lacks the preservative that prevents bacterial growth. Always use bacteriostatic water.
Inconsistent dosing: Skipping doses or varying timing significantly reduces outcomes. Set a daily alarm.
Poor storage: Reconstituted SS-31 must stay refrigerated at 2-8°C. Leaving it at room temperature degrades the compound rapidly.
Buying cheap: Low-cost peptides without COA testing may be underdosed, contaminated, or mislabeled. Quality matters more than price.
Bottom Line for SS-31 Beginners
Start at the lower end of 4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV, dose daily subcutaneous or weekly IV infusion, cycle for 12-48 weeks in clinical trials, and track everything. Source from COA-tested vendors and follow proper reconstitution protocol.
Read our complete peptide beginner's guide for general peptide education beyond SS-31.
Complete Guide
SS-31 (Elamipretide) : Mitochondrial Peptide for Energy & Aging
Related Reading
- SS-31 Dosage Guide
- SS-31 Benefits
- SS-31 Side Effects
- SS-31 Stacking Guide
- SS-31 Cycle Guide
- SS-31 Research
Research-Grade Sourcing
If you're going to research SS-31, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is SS-31?
SS-31 (Elamipretide (SS-31)) is a Mitochondrial-targeting tetrapeptide. Synthetic tetrapeptide co-discovered for mitochondrial dysfunction disorders; developed by Stealth BioTherapeutics. It is researched for improved muscle strength, enhanced cardiac function, increased ATP production, reduced oxidative stress, restored age-related mitochondrial dysfunction.
What is the recommended SS-31 dosage?
Common dosages: 4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV administered daily subcutaneous or weekly IV infusion via subcutaneous injection or intravenous infusion. Cycle length: 12-48 weeks in clinical trials. Half-life: approximately 20-30 minutes. Use our peptide calculator for exact reconstitution math.
What are the side effects of SS-31?
Excellent safety profile. No adverse events reported in single-dose IV studies. Well-tolerated across wide dose ranges in long-term Phase 2 and 3 trials.
Is SS-31 safe?
SS-31 has shown a favorable safety profile in research. FDA-approved September 2025 (FORZINITY) for Barth syndrome. Phase 3 trials ongoing for other indications. All research should follow appropriate safety protocols.